Moderna Inc

MRNA:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/15/21 EST
129.43quote price arrow down-0.22 (-0.17%)
Volume
278,295
Close
129.65quote price arrow down-0.07 (-0.05%)
Volume
15,366,379
52 week range
17.91 - 178.50

...

Loading . . .

KEY STATS

  • Open129.60
  • Day High133.29
  • Day Low126.58
  • Prev Close129.72
  • 52 Week High178.50
  • 52 Week High Date12/01/20
  • 52 Week Low17.91
  • 52 Week Low Date02/21/20
  • Market Cap51,303.80M
  • Shares Out395.71M
  • 10 Day Average Volume17.55M
  • Dividend-
  • Dividend Yield-
  • Beta1.74
  • 1 Year % Change517.09

RATIOS/PROFITABILITY

  • EPS (TTM)-1.62
  • P/E (TTM)-80.10
  • Fwd P/E (NTM)15.56
  • EBITDA (MRQ)-584.72M
  • ROE (MRQ)-29.80%
  • Revenue (MRQ)246.71M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-242.27%
  • Debt To Equity (MRQ)3.94%

EVENTS

  • Earnings Date02/24/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest MRNA News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Related Video

VIDEO1:3301:33
Moderna plans to test booster shot for Covid-19 vaccine trial patients

Profile

MORE
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced...
Noubar Afeyan Ph.D.
Non-Executive Chairman
Stephane Bancel
Chief Executive Officer
Stephen Hoge M.D.
President
David Meline
Chief Financial Officer
Juan Andres
Chief Technology Officer
Lori Henderson J.D.
General Counsel
Address
200 Technology Sq
Cambridge, MA
02139-3578
United States